These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 14679854)
21. Immunosuppressive treatment of the pulmonary manifestations of progressive systemic sclerosis. Vallance DK; Lynch JP; McCune WJ Curr Opin Rheumatol; 1995 May; 7(3):174-82. PubMed ID: 7612408 [TBL] [Abstract][Full Text] [Related]
22. [Systemic sclerosis-clinical picture, diagnosis, and treatment]. Becker MO; Distler O; Maurer B Z Rheumatol; 2019 Jun; 78(5):439-457. PubMed ID: 31089800 [TBL] [Abstract][Full Text] [Related]
23. Indirect evidence for the efficacy of methotrexate in diffuse systemic sclerosis. Low AH; Lee P J Rheumatol; 2008 Nov; 35(11):2286. PubMed ID: 19004063 [No Abstract] [Full Text] [Related]
24. Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Grassegger A; Schuler G; Hessenberger G; Walder-Hantich B; Jabkowski J; MacHeiner W; Salmhofer W; Zahel B; Pinter G; Herold M; Klein G; Fritsch PO Br J Dermatol; 1998 Oct; 139(4):639-48. PubMed ID: 9892907 [TBL] [Abstract][Full Text] [Related]
25. A case of systemic lupus erythematosus/systemic sclerosis overlap syndrome successfully treated with belimumab. Hara M; Ogawa-Momohara M; Muro Y; Takeichi T; Akiyama M Eur J Dermatol; 2020 Oct; 30(5):615-617. PubMed ID: 32972910 [No Abstract] [Full Text] [Related]
26. Observational data to study medication outcomes in systemic sclerosis. Hudson M; Baron M; ; Steele R J Rheumatol; 2011 Mar; 38(3):575-7. PubMed ID: 21362793 [No Abstract] [Full Text] [Related]
27. Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. Filaci G; Cutolo M; Basso M; Murdaca G; Derchi L; Gianrossi R; Ropolo F; Zentilin P; Sulli A; Puppo F; Indiveri F Rheumatology (Oxford); 2001 Dec; 40(12):1431-2. PubMed ID: 11752529 [No Abstract] [Full Text] [Related]
28. What can we learn from negative clinical trials in systemic sclerosis? Veale DJ Clin Exp Rheumatol; 2010; 28(2 Suppl 58):S1-4. PubMed ID: 20576207 [No Abstract] [Full Text] [Related]
29. Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies. Fett N Clin Dermatol; 2013; 31(4):432-437. PubMed ID: 23806160 [TBL] [Abstract][Full Text] [Related]
32. Treatment of systemic sclerosis. Medsger TA Ann Rheum Dis; 1991 Nov; 50 Suppl 4(Suppl 4):877-86. PubMed ID: 1750801 [TBL] [Abstract][Full Text] [Related]
33. Implications for the use of topoisomerase I inhibitors in treatment of patients with systemic sclerosis. Rudnicka L; Czuwara J; Barusińska A; Nowicka U; Makieła B; Jabłonska S Ann N Y Acad Sci; 1996 Dec; 803():318-20. PubMed ID: 8993528 [No Abstract] [Full Text] [Related]
34. Scleroderma in children. Zulian F Pediatr Clin North Am; 2005 Apr; 52(2):521-45, vii. PubMed ID: 15820378 [TBL] [Abstract][Full Text] [Related]
35. Treatment of complications associated with systemic sclerosis. Moore SC; Desantis ER Am J Health Syst Pharm; 2008 Feb; 65(4):315-21. PubMed ID: 18238768 [TBL] [Abstract][Full Text] [Related]
36. The treatment of systemic sclerosis. Black CM Adv Exp Med Biol; 1999; 455():271-7. PubMed ID: 10599354 [No Abstract] [Full Text] [Related]